Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2019
Event: Entry into a material definitive financing agreement and termination of a prior credit agreement.
Key Financial Metrics and Debt Structure
This filing details a new debt facility rather than operating performance metrics (revenue, profit, cash flow) for a specific period. Key financial terms include:
- Total Facility Size: $300 million first lien secured term loan.
- Initial Draw: $200 million drawn immediately upon execution.
- Interest Rate: 3-month LIBOR + 7.75% (LIBOR floor 2.70%) OR Prime Rate + 6.75% (Prime floor 5.20%).
- Repayment Schedule: Four equal quarterly installments beginning June 30, 2023; maturity date March 31, 2024.
- Prepayment Fees: 30% (Years 1-2), 5% (Year 3), 3% (Year 4), 1% (Year 5).
- Upfront Fees: 2.5% facility fee on initial borrowing ($5 million on the $200M tranche).
- Liquidity Covenant: Minimum unrestricted cash balance of $50 million (increasing to $60 million if additional tranches are drawn).
Material Changes Versus Prior Period
Debt Restructuring: The Company terminated its previous Credit and Security Agreement with MidCap Financial Trust (dated May 1, 2018). Approximately $81.7 million of the new initial tranche was used to repay the MidCap Agreement in full, including a 4% prepayment fee and a 4% repayment fee.
Capital Structure: The Company has shifted from the MidCap facility to a larger, secured term loan facility with TPG Specialty Lending, Inc., increasing total available debt capacity to $300 million subject to conditions.
Guidance, Outlook, and Conditions
Tranche Availability Conditions:
- Tranche 2 ($50 million): Available upon FDA designation of the ANNOVERA product as a new category of birth control by December 31, 2019.
- Tranche 3 ($50 million): Available upon achieving $11 million in net revenues from IMVEXXY, BIJUVA, and ANNOVERA products in Q4 2019.
Covenants and Risks:
- Revenue Covenants: The Company must achieve minimum consolidated net revenue amounts from commercial sales of IMVEXXY, BIJUVA, and ANNOVERA beginning in Q4 2020.
- Collateral: Obligations are secured by a first priority security interest in all existing and after-acquired assets of the Company and subsidiaries.
- Change of Control: The agreement includes an event of default relating to a change of control.
Management Commentary: The filing references a press release characterizing the financing as a "$300 Million Non-Dilutive Term Loan Financing Facility."
Investor Verification Checklist
- Verify the status of the FDA designation for ANNOVERA as a new category of birth control by December 31, 2019, to determine eligibility for the $50 million Tranche 2.
- Monitor Q4 2019 net revenue figures for IMVEXXY, BIJUVA, and ANNOVERA to assess eligibility for the $50 million Tranche 3.
- Review the Company's cash position to ensure compliance with the $50 million minimum unrestricted cash balance covenant.
- Confirm the impact of the 30% prepayment penalty on the Company's ability to refinance or repay debt within the first two years.
- Examine the full text of the Financing Agreement (to be filed as an exhibit to the Q2 2019 10-Q) for detailed representations, warranties, and events of default.